Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: A meta-analysis

British Journal of Dermatology

Volumn 164, Issue 4, 2011, Pages 776-784

  Lee, J H ^a   Choi, J W ^a   Kim, Young Sik ^a  

^a Korea University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE;

ARTICLE; CANCER LOCALIZATION; GENE FREQUENCY; GENE MUTATION; HISTOPATHOLOGY; HUMAN; MELANOMA; ONCOGENE N RAS; PARAMETER; PRIORITY JOURNAL;

AGE FACTORS; DNA MUTATIONAL ANALYSIS; FEMALE; GENE FREQUENCY; GENES, RAS; HUMANS; MALE; MELANOMA; MUTATION; ODDS RATIO; PROTO-ONCOGENE PROTEINS B-RAF; SEX FACTORS; SKIN NEOPLASMS;

EID: 79953723136     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2010.10185.x     Document Type: Article

References (54)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2009. CA Cancer J Clin 2009; 59:225-49.
2. Curtin JA, Fridlyand J, Kageshita T et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005; 353:2135-47. (Pubitemid 41653105)
3. Govindarajan B, Bai X, Cohen C et al. Malignant transformation of melanocytes to melanoma by constitutive activation of mitogen-activated protein kinase kinase (MAPKK) signaling. J Biol Chem 2003; 278:9790-5. (Pubitemid 36800479)
4. Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417:949-54. (Pubitemid 34716871)
5. Platz A, Egyhazi S, Ringborg U et al. Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site. Mol Oncol 2008; 1:395-405.
6. Dong J, Phelps RG, Qiao R et al. BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma. Cancer Res 2003; 63:3883-5. (Pubitemid 36917898)
7. Yazdi AS, Palmedo G, Flaig MJ et al. Mutations of the BRAF gene in benign and malignant melanocytic lesions. J Invest Dermatol 2003; 121:1160-2. (Pubitemid 37430987)
8. Kumar R, Angelini S, Hemminki K. Activating BRAF and N-Ras mutations in sporadic primary melanomas: an inverse association with allelic loss on chromosome 9. Oncogene 2003; 22:9217-24. (Pubitemid 38122033)
9. Shinozaki M, Fujimoto A, Morton DL et al. Incidence of BRAF oncogene mutation and clinical relevance for primary cutaneous melanomas. Clin Cancer Res 2004; 10:1753-7. (Pubitemid 38435567)
10. Reifenberger J, Knobbe CB, Sterzinger AA et al. Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas. Int J Cancer 2004; 109:377-84. (Pubitemid 38252766)
11. Sasaki Y, Niu C, Makino R et al. BRAF point mutations in primary melanoma show different prevalences by subtype. J Invest Dermatol 2004; 123:177-83. (Pubitemid 38833479)
12. Davison JM, Rosenbaum E, Barrett TL et al. Absence of V599E BRAF mutations in desmoplastic melanomas. Cancer 2005; 103:788-92. (Pubitemid 40216408)
13. Goydos JS, Mann B, Kim HJ et al. Detection of B-RAF and N-RAS mutations in human melanoma. J Am Coll Surg 2005; 200:362-70. (Pubitemid 40298970)
14. Turner DJ, Zirvi MA, Barany F et al. Detection of the BRAF V600E mutation in melanocytic lesions using the ligase detection reaction. J Cutan Pathol 2005; 32:334-9. (Pubitemid 40547791)
15. Wong CW, Fan YS, Chan TL et al. BRAF and NRAS mutations are uncommon in melanomas arising in diverse internal organs. J Clin Pathol 2005; 58:640-4. (Pubitemid 40814027)
16. Libra M, Malaponte G, Navolanic PM et al. Analysis of BRAF mutation in primary and metastatic melanoma. Cell Cycle 2005; 4:1382-4. (Pubitemid 41437127)
17. Lang J, MacKie RM. Prevalence of exon 15 BRAF mutations in primary melanoma of the superficial spreading, nodular, acral, and lentigo maligna subtypes. J Invest Dermatol 2005; 125:575-9.
18. Goel VK, Lazar AJ, Warneke CL et al. Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma. J Invest Dermatol 2006; 126:154-60. (Pubitemid 43336107)
19. Lee DA, Cohen JA, Twaddell WS et al. Are all melanomas the same? Spitzoid melanoma is a distinct subtype of melanoma. Cancer 2006; 106:907-13. (Pubitemid 43238459)
20. Deichmann M, Krahl D, Thome M et al. The oncogenic B-raf V599E mutation occurs more frequently in melanomas at sun-protected body sites. Int J Oncol 2006; 29:139-45.
21. Lassacher A, Worda M, Kaddu S et al. T1799A BRAF mutation is common in PUVA lentigines. J Invest Dermatol 2006; 126:1915-17.
22. Poynter JN, Elder JT, Fullen DR et al. BRAF and NRAS mutations in melanoma and melanocytic nevi. Melanoma Res 2006; 16:267-73. (Pubitemid 44090170)
23. Saldanha G, Potter L, Daforno P et al. Cutaneous melanoma subtypes show different BRAF and NRAS mutation frequencies. Clin Cancer Res 2006; 12:4499-505. (Pubitemid 44297798)
24. Edlundh-Rose E, Egyhazi S, Omholt K et al. NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing. Melanoma Res 2006; 16:471-8. (Pubitemid 44934704)
25. Liu W, Kelly JW, Trivett M et al. Distinct clinical and pathological features are associated with the BRAF(T1799A(V600E)) mutation in primary melanoma. J Invest Dermatol 2007; 127:900-5. (Pubitemid 46434654)
26. Thomas NE, Edmiston SN, Alexander A et al. Number of nevi and early-life ambient UV exposure are associated with BRAF-mutant melanoma. Cancer Epidemiol Biomarkers Prev 2007; 16:991-7. (Pubitemid 46910102)
27. Takata M, Lin J, Takayanagi S et al. Genetic and epigenetic alterations in the differential diagnosis of malignant melanoma and spitzoid lesion. Br J Dermatol 2007; 156:1287-94. (Pubitemid 47029852)
28. Akslen LA, Puntervoll H, Bachmann IM et al. Mutation analysis of the EGFR-NRAS-BRAF pathway in melanomas from black Africans and other subgroups of cutaneous melanoma. Melanoma Res 2008; 18:29-35. (Pubitemid 351628053)
29. Fargnoli MC, Pike K, Pfeiffer RM et al. MC1R variants increase risk of melanomas harboring BRAF mutations. J Invest Dermatol 2008; 128:2485-90.
30. Venesio T, Chiorino G, Balsamo A et al. In melanocytic lesions the fraction of BRAF V600E alleles is associated with sun exposure but unrelated to ERK phosphorylation. Mod Pathol 2008; 21:716-26.
31. Jovanovic B, Krockel D, Linden D et al. Lack of cytoplasmic ERK activation is an independent adverse prognostic factor in primary cutaneous melanoma. J Invest Dermatol 2008; 128:2696-704.
32. Viros A, Fridlyand J, Bauer J et al. Improving melanoma classification by integrating genetic and morphologic features. PLoS Med 2008; 5:e120.
33. Dadzie OE, Yang S, Emley A et al. RAS and RAF mutations in banal melanocytic aggregates contiguous with primary cutaneous melanoma: clues to melanomagenesis. Br J Dermatol 2009; 160:368-75.
34. Daniotti M, Ferrari A, Frigerio S et al. Cutaneous melanoma in childhood and adolescence shows frequent loss of INK4A and gain of KIT. J Invest Dermatol 2009; 129:1759-68.
35. Kannengiesser C, Spatz A, Michiels S et al. Gene expression signature associated with BRAF mutations in human primary cutaneous melanomas. Mol Oncol 2008; 1:425-30.
36. Beadling C, Jacobson-Dunlop E, Hodi FS et al. KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res 2008; 14:6821-8.
37. Uribe P, Wistuba II, Gonzalez S. Allelotyping, microsatellite instability, and BRAF mutation analyses in common and atypical melanocytic nevi and primary cutaneous melanomas. Am J Dermatopathol 2009; 31:354-63.
38. Greene VR, Johnson MM, Grimm EA et al. Frequencies of NRAS and BRAF mutations increase from the radial to the vertical growth phase in cutaneous melanoma. J Invest Dermatol 2009; 129:1483-8.
39. Hacker E, Hayward NK, Dumenil T et al. The association between MC1R genotype and BRAF mutation status in cutaneous melanoma: findings from an Australian population. J Invest Dermatol 2010; 130:241-8.
40. Lázár V, Ecsedi S, Szöllosi AG et al. Characterization of candidate gene copy number alterations in the 11q13 region along with BRAF and NRAS mutations in human melanoma. Mod Pathol 2009; 22:1367-78.
41. Casula M, Muggiano A, Cossu A et al. Role of key-regulator genes in melanoma susceptibility and pathogenesis among patients from South Italy. BMC Cancer 2009; 9:352.
42. Shukla VK, Hughes DC, Hughes LE et al. Ras mutations in human melanotic lesions: K-ras activation is a frequent and early event in melanoma development. Oncogene Res 1989; 5:121-7. (Pubitemid 20018406)
43. van't Veer LJ, Burgering BM, Versteeg R et al. N-ras mutations in human cutaneous melanoma from sun-exposed body sites. Mol Cell Biol 1989; 9:3114-16.
44. Albino AP, Nanus DM, Mentle IR et al. Analysis of ras oncogenes in malignant melanoma and precursor lesions: correlation of point mutations with differentiation phenotype. Oncogene 1989; 4:1363-74. (Pubitemid 19273392)
45. Ball NJ, Yohn JJ, Morelli JG et al. Ras mutations in human melanoma: a marker of malignant progression. J Invest Dermatol 1994; 102:285-90.
46. Carr J, Mackie RM. Point mutations in the N-ras oncogene in malignant melanoma and congenital naevi. Br J Dermatol 1994; 131:72-7. (Pubitemid 24234291)
47. Wagner SN, Ockenfels HM, Wagner C et al. Ras gene mutations: a rare event in nonmetastatic primary malignant melanoma. J Invest Dermatol 1995; 104:868-71.
48. van Elsas A, Zerp SF, van der Flier S et al. Relevance of ultraviolet-induced N-ras oncogene point mutations in development of primary human cutaneous melanoma. Am J Pathol 1996; 149:883-93. (Pubitemid 26334172)
49. Demunter A, Ahmadian MR, Libbrecht L et al. A novel N-ras mutation in malignant melanoma is associated with excellent prognosis. Cancer Res 2001; 61:4916-22. (Pubitemid 32691910)
50. Eliopoulos AG, Kiaris H, Rees RC et al. Ras gene mutations are a rare event in human uveal and cutaneous melanomas. Oncol Rep 1994; 1:571-5. (Pubitemid 2070028)
51. Tsao H, Goel V, Wu H et al. Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. J Invest Dermatol 2004; 122:337-41. (Pubitemid 38281053)
52. Lee JH, Lee ES, Kim YS. Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid: a meta-analysis. Cancer 2007; 110:38-46.
53. DeLuca AM, Srinivas A, Alani RM. BRAF kinase in melanoma development and progression. Expert Rev Mol Med 2008; 10:e6.
54. Singh M, Lin J, Hocker TL et al. Genetics of melanoma tumorigenesis. Br J Dermatol 2008; 158:15-21. (Pubitemid 350221925)